| Primary |
| Insulin-like Growth Factor Decreased |
26.0% |
| Body Height Below Normal |
11.9% |
| Product Used For Unknown Indication |
11.7% |
| Growth Hormone Deficiency |
10.7% |
| Primary Insulin Like Growth Factor-1 Deficiency |
9.2% |
| Growth Retardation |
5.6% |
| Off Label Use |
4.4% |
| Failure To Thrive |
3.4% |
| Rett's Disorder |
2.9% |
| Convulsion |
2.2% |
| Foetal Growth Restriction |
1.9% |
| Blood Growth Hormone Abnormal |
1.7% |
| Drug Use For Unknown Indication |
1.7% |
| Insulin Resistance Syndrome |
1.2% |
| Insulin-like Growth Factor Increased |
1.2% |
| Autosomal Chromosome Anomaly |
1.0% |
| Dwarfism |
1.0% |
| Depression |
0.7% |
| Ear Infection |
0.7% |
| Hypopituitarism |
0.7% |
|
| Urticaria |
13.2% |
| Injection Site Urticaria |
12.5% |
| Hypoglycaemia |
7.6% |
| Tonsillar Hypertrophy |
7.6% |
| Vomiting |
6.9% |
| Headache |
5.6% |
| Convulsion |
4.9% |
| Papilloedema |
4.9% |
| Blood Glucose Increased |
3.5% |
| Hair Texture Abnormal |
3.5% |
| Injection Site Swelling |
3.5% |
| Loss Of Consciousness |
3.5% |
| Osteonecrosis |
3.5% |
| Aggression |
2.8% |
| Alopecia |
2.8% |
| Hydrocele |
2.8% |
| Injection Site Pain |
2.8% |
| Injection Site Pruritus |
2.8% |
| Off Label Use |
2.8% |
| Thyroid Neoplasm |
2.8% |
|
| Secondary |
| Product Used For Unknown Indication |
24.3% |
| Depression |
20.9% |
| Primary Insulin Like Growth Factor-1 Deficiency |
13.9% |
| Insulin-like Growth Factor Decreased |
10.4% |
| Micturition Urgency |
7.0% |
| Precocious Puberty |
7.0% |
| Growth Hormone Deficiency |
6.1% |
| Pyrexia |
5.2% |
| Ear Infection |
2.6% |
| Body Height Below Normal |
0.9% |
| Dwarfism |
0.9% |
| Insulin-like Growth Factor |
0.9% |
|
| Encopresis |
23.5% |
| Optic Nerve Disorder |
14.7% |
| Thyroid Neoplasm |
14.7% |
| Tonsillar Hypertrophy |
8.8% |
| Urticaria |
8.8% |
| Constipation |
5.9% |
| Volvulus Of Small Bowel |
5.9% |
| Abdominal Pain |
2.9% |
| Fatigue |
2.9% |
| Headache |
2.9% |
| Injection Site Urticaria |
2.9% |
| Ocular Hyperaemia |
2.9% |
| Thrombocytopenia |
2.9% |
|
| Concomitant |
| Growth Retardation |
33.3% |
| Foetal Growth Restriction |
22.2% |
| Growth Hormone Deficiency |
22.2% |
| Product Used For Unknown Indication |
22.2% |
|
| Chronic Myelomonocytic Leukaemia |
37.5% |
| Dysplasia |
25.0% |
| Fibroma |
12.5% |
| Implant Site Papules |
12.5% |
| Jaw Disorder |
12.5% |
|
